title: Phase II pilot study of oral dasatinib in patients with higher-risk myelodysplastic syndrome (MDS) who failed conventional therapy.
abstract: Given evidence for the role of Src family kinases, especially Lyn kinase, in myeloblast proliferation and the in vitro inhibitory activity of dasatinib on Src and Lyn, we conducted a phase II study to assess overall response to 100mg/day dasatinib in patients with higher-risk myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia, or acute myeloid leukemia arising from MDS and who had failed prior treatment with azanucleoside analogs. Among 18 patients treated, 3 responded, 4 had stable disease, and 10 experienced disease progression. Toxicities were limited and consistent with previous reports. Dasatinib appears to be safe but with limited efficacy.
authors.affiliation: University of Maryland Greenebaum Cancer Center, Baltimore, MD, United States.
authors.forename: Vu H
authors.initials: VH
authors.lastname: Duong
authors.forename: Michael V
authors.initials: MV
authors.lastname: Jaglal
authors.forename: Ling
authors.initials: L
authors.lastname: Zhang
authors.forename: Vishakha
authors.initials: V
authors.lastname: Kale
authors.forename: Jeffrey E
authors.initials: JE
authors.lastname: Lancet
authors.forename: Rami S
authors.initials: RS
authors.lastname: Komrokji
authors.forename: Alan F
authors.initials: AF
authors.lastname: List
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D000069439:Dasatinib; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000401:mortality; D010865:Pilot Projects; D011743:Pyrimidines / Q000008:administration & dosage* / Q000009:adverse effects; D012306:Risk; D016879:Salvage Therapy; D012720:Severity of Illness Index; D059039:Standard of Care; D013844:Thiazoles / Q000008:administration & dosage* / Q000009:adverse effects; D017211:Treatment Failure
chemical_list: D000970:Antineoplastic Agents; D011743:Pyrimidines; D013844:Thiazoles; D000069439:Dasatinib